enGene Therapeutics Inc. SEC filings ENGNW
enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 9, 2026 | — |
| 424B5 | Prospectus supplement | Mar 9, 2026 | — |
| S-3 | Shelf registration | Feb 19, 2026 | — |
| 424B5 | Prospectus supplement | Nov 14, 2025 | — |
| 424B5 | Prospectus supplement | Nov 12, 2025 | — |
| S-8 | Employee stock plan registration | Sep 11, 2025 | — |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| 424B5 | Prospectus supplement | Dec 20, 2024 | — |
| 424B3 | Prospectus | Nov 21, 2024 | — |
| 424B3 | Prospectus | Nov 21, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| 424B3 | Prospectus | Oct 28, 2024 | — |
| 424B3 | Prospectus | Oct 21, 2024 | — |
| 424B3 | Prospectus | Sep 26, 2024 | — |
| 424B3 | Prospectus | Sep 10, 2024 | — |
| 424B3 | Prospectus | Jul 24, 2024 | — |
| 424B3 | Prospectus | Jun 14, 2024 | — |
| 424B3 | Prospectus | May 15, 2024 | — |
| 424B3 | Prospectus | Apr 25, 2024 | — |
| 424B3 | Prospectus | Mar 12, 2024 | — |
| 424B3 | Prospectus | Mar 5, 2024 | — |
| S-8 | Employee stock plan registration | Feb 27, 2024 | — |
| S-1/A | Amended registration statement | Feb 27, 2024 | — |
| S-1/A | Amended registration statement | Dec 15, 2023 | — |
| S-1 | Registration statement | Nov 22, 2023 | — |
| 424B3 | Prospectus | Oct 2, 2023 | — |
| S-4/A | Filing | Sep 26, 2023 | — |
| S-4/A | Filing | Aug 30, 2023 | — |
| S-4 | Registration for a merger or exchange | Aug 9, 2023 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.